aficamten (Myqorzo)

Indications

• treatment of symptomatic obstructive hypertrophic cardiomyopathy

Contraindications

• avoid in patients with LVEF < 55%

Dosage

• start 5 mg QD
• tablets 5, 10, 15, 20 mg

Adverse effects

• heart failure

Drug interactions

• contraindicated with rifampin

Mechanism of action

• allosteric & reversible inhibitor of cardiac myosin
• reduces cardiac contractility & left ventricular outflow tract obstruction

More general terms

• cardiotonic agent

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=139331495